These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38851203)

  • 61. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
    Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Broadening horizons with
    Ballal S; Yadav MP; Bal C; Sahoo RK; Tripathi M
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):934-946. PubMed ID: 31707430
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913).
    Riesco-Martinez MC; Capdevila J; Alonso V; Jimenez-Fonseca P; Teule A; Grande E; Sevilla I; Benavent M; Alonso-Gordoa T; Custodio A; Anton-Pascual B; Hernando J; Polo E; Castillo-Trujillo OA; Lamas-Paz A; Teijo A; Rodriguez-Gil Y; Soldevilla B; Garcia-Carbonero R
    Nat Commun; 2024 Aug; 15(1):6753. PubMed ID: 39117670
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.
    Delpassand ES; Samarghandi A; Zamanian S; Wolin EM; Hamiditabar M; Espenan GD; Erion JL; O'Dorisio TM; Kvols LK; Simon J; Wolfangel R; Camp A; Krenning EP; Mojtahedi A
    Pancreas; 2014 May; 43(4):518-25. PubMed ID: 24632546
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
    Thakral P; Sen I; Pant V; Gupta SK; Dureja S; Kumari J; Kumar S; Un P; Malasani V
    Br J Radiol; 2018 Nov; 91(1091):20170172. PubMed ID: 30028180
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors.
    Sansovini M; Severi S; Ambrosetti A; Monti M; Nanni O; Sarnelli A; Bodei L; Garaboldi L; Bartolomei M; Paganelli G
    Neuroendocrinology; 2013; 97(4):347-54. PubMed ID: 23392072
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.
    Kwekkeboom DJ; de Herder WW; Kam BL; van Eijck CH; van Essen M; Kooij PP; Feelders RA; van Aken MO; Krenning EP
    J Clin Oncol; 2008 May; 26(13):2124-30. PubMed ID: 18445841
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Desmoplastic mesenteric lesions do not respond radiographically to peptide receptor radionuclide therapy.
    Pelle E; Al-Toubah T; Morse B; El-Haddad G; Strosberg J
    J Neuroendocrinol; 2021 Feb; 33(2):e12936. PubMed ID: 33474756
    [No Abstract]   [Full Text] [Related]  

  • 69. Long-term efficacy of (90)Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms.
    Rogowski W; Wachuła E; Lewczuk A; Buscombe JR; Seklecka N; Sankowski A; Ćwikła JB
    Future Oncol; 2016 Aug; 12(16):1877-85. PubMed ID: 27156864
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prediction of
    Mileva M; Marin G; Levillain H; Artigas C; Van Bogaert C; Marin C; Danieli R; Deleporte A; Picchia S; Stathopoulos K; Jungels C; Vanderlinden B; Paesmans M; Ameye L; Critchi G; Taraji-Schiltz L; Velghe C; Wimana Z; Bali M; Hendlisz A; Flamen P; Karfis I
    J Nucl Med; 2024 Feb; 65(2):236-244. PubMed ID: 38164576
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting.
    Kalshetty A; Ramaswamy A; Ostwal V; Basu S
    Nucl Med Commun; 2018 Dec; 39(12):1143-1149. PubMed ID: 30308585
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The effect of long-acting somatostatin analogues on the uptake of [
    Veerman CHAM; Siebinga H; de Vries-Huizing DMV; Tesselaar MET; Hendrikx JJMA; Stokkel MPM; Aalbersberg EA
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1434-1441. PubMed ID: 36598536
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
    Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
    Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.
    Bodei L; Cremonesi M; Grana CM; Fazio N; Iodice S; Baio SM; Bartolomei M; Lombardo D; Ferrari ME; Sansovini M; Chinol M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2011 Dec; 38(12):2125-35. PubMed ID: 21892623
    [TBL] [Abstract][Full Text] [Related]  

  • 75. (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours: 5 years' experience from a tertiary cancer care centre in India.
    Danthala M; Kallur KG; Prashant GR; Rajkumar K; Raghavendra Rao M
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1319-26. PubMed ID: 24570096
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Investigation of receptor radionuclide therapy with
    Nicolini S; Severi S; Ianniello A; Sansovini M; Ambrosetti A; Bongiovanni A; Scarpi E; Di Mauro F; Rossi A; Matteucci F; Paganelli G
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):923-930. PubMed ID: 29387927
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The efficacy of
    Zhang J; Song Q; Cai L; Xie Y; Chen Y
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1533-1543. PubMed ID: 32281025
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog
    Liu Q; Cheng Y; Zang J; Sui H; Wang H; Jacobson O; Zhu Z; Chen X
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):947-957. PubMed ID: 31832728
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours.
    van Essen M; Krenning EP; Kam BL; de Herder WW; van Aken MO; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):743-8. PubMed ID: 18188559
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis.
    Ryan P; McBride A; Ray D; Pulgar S; Ramirez RA; Elquza E; Favaro JP; Dranitsaris G
    J Oncol Pharm Pract; 2019 Sep; 25(6):1425-1433. PubMed ID: 30924737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.